R&D channel feed – Endpoints News

R&D channel feed

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

9 years ago

Alexion adds a failed pivotal Soliris trial to an air of crisis. The perfect time to talk buyout

9 years ago

Galapagos, AbbVie glimpse early progress in search of a cystic fibrosis triple to rival Vertex

9 years ago

Merrimack shutters a failing PhII breast cancer study for MM-302

9 years ago

Acadia shares skid as Nuplazid clears mid-stage hurdle for Alzheimer’s psychosis, but skeptics pounce

9 years ago

Akebia forges $1B US pact with Otsuka on lead drug for CKD, shares spike

9 years ago

Watch out Gilead, GSK’s ViiV is steaming ahead with promising late-stage data on a two-drug HIV therapy

9 years ago

Microcap Conatus teams up with pharma giant Novartis on NASH drug, shares rocket up

9 years ago

After an R&D odyssey filled with setbacks, Clovis wins an FDA OK for rucaparib

9 years ago

Ionis reports a positive PhIII for volanesorsen in rare metabolic disorders

9 years ago

Yes, Loxo is still planning on seeking an accelerated OK, in case you had forgotten

9 years ago

Xtandi fails a combo study, blocking a path to continued use for Pfizer, Astellas

9 years ago

INC Research promises 550 new jobs as it plots headquarters move

9 years ago

Bristol-Myers outlines a big R&D overhaul covering East, West Coast operations

9 years ago

Kyowa Hakko Kirin hit with a new PhIII setback on an old Parkinson’s drug

9 years ago

GSK preps for vaccine R&D expansion, 200 hires for new global hub

9 years ago

Proteon triggers a stock implosion as its first PhIII proves to be a bust

9 years ago

Learning from past mistakes, Centrexion clears a big PhIIb hurdle for its pain drug

9 years ago

Big Pharma’s woeful numbers on drug R&D just got even worse

9 years ago

Gates-backed Exicure wraps 2016 with its first major collaboration and a plan for the year ahead

9 years ago

Achaogen slowly soars, speeding top antibiotic to FDA/EMA after PhIII scores positive results

9 years ago

Novartis-allied Ophthotech blitzed after a pair of PhIII disasters for wet-AMD franchise drug

9 years ago

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

9 years ago

Moving on past sola wreckage, Lilly doubles down on one more Alzheimer’s drug from AstraZeneca

9 years ago

First page Previous page 309 310 311312313 314 315 Next page Last page